Clinical Trials Browser

Phase 1/2 × OTHER_GOV × surufatinib × Clear all

NCT05882630 2023-05-31

Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer

Phase 1/2 Not yet recruiting

Small Cell Lung Carcinoma